The LEVEL data is a mixed bag—primary miss but strong biomarker and subgroup signals. The stock has already moved significantly on the topline results (released Aug 10). This comprehensive update provides no new binary catalyst; it reinforces the de-risking narrative for LEVEL-2. Monitor for the LEVEL-2 protocol design paper and enrollment updates in 2026-1H 2027.
Price Chart
Executive Summary
Tenax Therapeutics presented a comprehensive update on its Phase 3 LEVEL trial of oral levosimendan (TNX-103) in PH-HFpEF at the Cantor Conference. The trial missed its primary 6MWD endpoint (p=0.63), but showed a 49% reduction in NT-proBNP (p<0.0001) and a 3.5 mmHg reduction in RVSP. A prespecified subgroup analysis in patients with baseline 6MWD below the median (<333m) showed a +26.3m treatment effect (p=0.0112), which the company is using to de-risk the upcoming LEVEL-2 trial. The filing is a routine investor presentation update with no new financial data or guidance.
Key Facts
- Phase 3 LEVEL trial of TNX-103 (oral levosimendan) in PH-HFpEF missed its primary 6MWD endpoint (LS mean difference 3.5m, p=0.63).
- NT-proBNP was reduced by 49% vs placebo (p<0.0001), the largest reduction to date in an HFpEF RCT.
- RVSP was reduced by 3.5 mmHg in the overall population (p=0.0045) and by 4.9 mmHg in patients with baseline 6MWD <333m (p=0.0090).
- In a prespecified subgroup with baseline 6MWD <333m, the treatment effect on 6MWD was +26.3m (95% CI: 6.0, 46.7; nominal p=0.0112).
- Safety profile showed higher rates of treatment-related AEs on drug (38.3% vs 17.4%), but serious AEs and clinical worsening events were balanced across arms.
- The company is using LEVEL insights to strategically reshape the LEVEL-2 protocol with enriched patient selection.
Financial Impact
No financial data or guidance provided in the filing.
Risk Factors
- Primary endpoint miss in LEVEL could undermine regulatory path if FDA requires a positive Phase 3 on 6MWD.
- Subgroup analysis (baseline 6MWD <333m) is post-hoc and may not replicate in LEVEL-2.
- Higher treatment-related AE rates (38.3% vs 17.4%) and discontinuations (8.3% vs 1.7%) on drug could limit commercial adoption.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-385910 |
| Document: d43255d8k.htm | 0001193125-26-385910 |
| Document: 0001193125-26-385910-index-headers.html | 0001193125-26-385910 |
| Document: 0001193125-26-385910-index.html | 0001193125-26-385910 |
| Document: 0001193125-26-385910.txt | 0001193125-26-385910 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | SC 13G/A | $1.36 $1.72 | ▲ +26.47% | ▲ +26.90% | $1.76 (+29.41%) |
Oct 13, 2026 14d ago | SC 13G/A | $1.60 $1.63 | ▲ +1.88% | ▲ +3.03% | $1.76 (+10.00%) |
Oct 9, 2026 17d ago | SC 13G/A | $1.83 $1.52 | ▼ −16.94% | ▼ −15.45% | $1.76 (−3.83%) |
Oct 8, 2026 18d ago | 8-K | $1.87 $1.36 | ▼ −27.27% | ▼ −25.30% | $1.76 (−5.88%) |
Sep 17, 2026 5w ago | Insider Cluster | $1.90 $1.81 | ▼ −4.74% | ▼ −6.01% | $1.76 (−7.37%) |
Sep 9, 2026 6w ago | 8-K | $2.13 $1.82 | ▼ −14.55% | ▼ −13.90% | $1.76 (−17.37%) |
Aug 29, 2026 8w ago | Press Release | $1.84 $2.05 | ▲ +11.20% | ▲ +11.34% | $1.76 (−4.35%) |
Aug 10, 2026 11w ago | 8-K | $1.38 $1.71 | ▲ +24.36% | ▲ +24.41% | $1.76 (+28.00%) |
Aug 10, 2026 11w ago | Press Release | $1.38 $1.71 | ▲ +24.36% | ▲ +24.41% | $1.76 (+28.00%) |
Jul 31, 2026 12w ago | 8-K | $13.70 $13.44 | ▼ −1.90% | ▼ −5.41% | $1.76 (−87.15%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers